Indeed, knocking down or over-expressing one of these targets downstream of treating with IL-6 or p38 inhibition would further highlight the molecules that may connect both IL-6 and p38 pathways and their relevance to PCa progression. The gene discussed is MAPK14; the disease is posterior cortical atrophy.